← brief for 2026-09-08 · Slowing decline

Kidney Disease: Improving Global Outcomes (KDIGO) responds to the retraction of the ADVOCATE trial of avacopan for the treatment of ANCA-associated vasculitis

Paper No results yet Not peer reviewed

Key takeaways

KDIGO, the group that writes global kidney treatment guidelines, has responded to the retraction of the ADVOCATE trial. That trial was the main basis for approving avacopan, a pill for ANCA-associated vasculitis, a disease where the immune system attacks small blood vessels and often destroys kidney function. Avacopan was approved in the United States in 2021 and later in Japan, Europe and the United Kingdom on that evidence. This is a statement, not a study, so there are no new results, but it may change what doctors are advised to do.

Source

Paper · Kidney International · 2026-09-08
https://www.kidney-international.org/article/S0085-2538(26)00723-4/fulltext?rss=yes